Pfizer's Q4 Earnings in Focus: Post-Pandemic Revenue Shift and Pipeline Progress to Steer Investor Sentiment
As Pfizer prepares to report its fourth-quarter results, investors are weighing the company's strategic pivot beyond its COVID-19 portfolio against a backdrop of expected revenue declines. The report may set the tone for the broader pharmaceutical sector.